Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T05:21:41.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T11:08:47.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-27T04:24:50.000Z thumbnail image
  8. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T02:32:28.000Z thumbnail image
  9. Check
    26 days ago
    Change Detected
    Summary
    The value 'Show more Revision: v2.9.0' has been updated to 'MedlinePlus related topics: Thyroid Cancer, Thyroid Diseases, Genetic and Rare Diseases Information Center resources: Papillary Thyroid Carcinoma, Thyroid Cancer, Follicular, Drug Information available for: Cabozantinib, FDA Drug and Device Resources'. This change reflects additional information related to the study and resources available.
    Difference
    19%
    Check dated 2024-06-25T02:08:32.000Z thumbnail image
  10. Check
    30 days ago
    Change Detected
    Summary
    The change in value from 'No publications available' to the publication of 'Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial' in the Lancet Oncology journal represents the addition of a significant study publication related to the study of Cabozantinib in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer.
    Difference
    5%
    Check dated 2024-06-20T21:03:28.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.